LeMaitre Vascular Inc has a consensus price target of $56.75, established from looking at the 12 latest analyst ratings. The last 3 analyst ratings were released from Barrington Research, Keybanc, and JMP Securities on February 28, 2024, February 6, 2024, and October 23, 2023. With an average price target of $43 between Barrington Research, Keybanc, and JMP Securities, there's an implied -36.01% downside for LeMaitre Vascular Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/28/2024 | LMAT | Buy Now | LeMaitre Vascular | $67.20 | 2.68% | Barrington Research | Michael Petusky | $66 → $69 | Maintains | Outperform | Get Alert |
02/06/2024 | LMAT | Buy Now | LeMaitre Vascular | $67.20 | — | Keybanc | Brett Fishbin | — | Initiates | → Sector Weight | Get Alert |
10/23/2023 | LMAT | Buy Now | LeMaitre Vascular | $67.20 | -10.71% | JMP Securities | Daniel Stauder | → $60 | Initiates | → Market Outperform | Get Alert |
09/06/2023 | LMAT | Buy Now | LeMaitre Vascular | $67.20 | 4.17% | Oppenheimer | Suraj Kalia | → $70 | Initiates | → Outperform | Get Alert |
08/03/2023 | LMAT | Buy Now | LeMaitre Vascular | $67.20 | -0.3% | Jefferies | Anthony Petrone | $63 → $67 | Downgrade | Buy → Hold | Get Alert |
08/02/2023 | LMAT | Buy Now | LeMaitre Vascular | $67.20 | 11.61% | Lake Street | Brooks O'Neil | $65 → $75 | Maintains | Buy | Get Alert |
08/02/2023 | LMAT | Buy Now | LeMaitre Vascular | $67.20 | -1.79% | Barrington Research | Michael Petusky | $62 → $66 | Maintains | Outperform | Get Alert |
05/03/2023 | LMAT | Buy Now | LeMaitre Vascular | $67.20 | -7.74% | Barrington Research | Michael Petusky | → $62 | Upgrade | Market Perform → Outperform | Get Alert |
10/28/2022 | LMAT | Buy Now | LeMaitre Vascular | $67.20 | — | Barrington Research | Michael Petusky | — | Downgrade | Outperform → Market Perform | Get Alert |
09/16/2021 | LMAT | Buy Now | LeMaitre Vascular | $67.20 | 4.17% | Jefferies | Anthony Petrone | — | Initiates | → Buy | Get Alert |
08/03/2021 | LMAT | Buy Now | LeMaitre Vascular | $67.20 | -13.69% | Roth Capital | Scott Henry | — | Maintains | Neutral | Get Alert |
05/04/2021 | LMAT | Buy Now | LeMaitre Vascular | $67.20 | -18.15% | Roth Capital | — | — | Maintains | Neutral | Get Alert |
The latest price target for LeMaitre Vascular (NASDAQ: LMAT) was reported by Barrington Research on February 28, 2024. The analyst firm set a price target for $69.00 expecting LMAT to rise to within 12 months (a possible 2.68% upside). 8 analyst firms have reported ratings in the last year.
The latest analyst rating for LeMaitre Vascular (NASDAQ: LMAT) was provided by Barrington Research, and LeMaitre Vascular maintained their outperform rating.
The last upgrade for LeMaitre Vascular Inc happened on May 3, 2023 when Barrington Research raised their price target to $62. Barrington Research previously had a market perform for LeMaitre Vascular Inc.
The last downgrade for LeMaitre Vascular Inc happened on August 3, 2023 when Jefferies changed their price target from $63 to $67 for LeMaitre Vascular Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of LeMaitre Vascular, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for LeMaitre Vascular was filed on February 28, 2024 so you should expect the next rating to be made available sometime around February 28, 2025.
While ratings are subjective and will change, the latest LeMaitre Vascular (LMAT) rating was a maintained with a price target of $66.00 to $69.00. The current price LeMaitre Vascular (LMAT) is trading at is $67.20, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.